[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=bae992baddad947c86da3c75df19021d40c143d3ca5538e8745e65d3ca1ee8b5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731947700,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 131473439,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=bae992baddad947c86da3c75df19021d40c143d3ca5538e8745e65d3ca1ee8b5"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe",
    "summary": "The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.",
    "url": "https://finnhub.io/api/news?id=5980f8c38830ed6f793efe3e869fc65b32d927512ebeae320d84a5511a371c43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731943020,
      "headline": "AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe",
      "id": 131456379,
      "image": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.",
      "url": "https://finnhub.io/api/news?id=5980f8c38830ed6f793efe3e869fc65b32d927512ebeae320d84a5511a371c43"
    }
  },
  {
    "ts": null,
    "headline": "Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products",
    "summary": "Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to all Allergan Aesthetics customers. This innovative offering empowers healthcare practitioners, their staff, and management with business education practices focused on Allergan Aesthetics products to enhance patient service and achieve operational excellence.",
    "url": "https://finnhub.io/api/news?id=d941146d98ef280aa0d52aa5190f5391334fd9a337a7f066050c72a24d4cba55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731938400,
      "headline": "Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products",
      "id": 131456383,
      "image": "https://media.zenfs.com/en/prnewswire.com/d07e572eaef73a27c1ae25977c221fa1",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to all Allergan Aesthetics customers. This innovative offering empowers healthcare practitioners, their staff, and management with business education practices focused on Allergan Aesthetics products to enhance patient service and achieve operational excellence.",
      "url": "https://finnhub.io/api/news?id=d941146d98ef280aa0d52aa5190f5391334fd9a337a7f066050c72a24d4cba55"
    }
  },
  {
    "ts": null,
    "headline": "Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients",
    "summary": "Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it prepares for the ARTEMIS study in 2025.",
    "url": "https://finnhub.io/api/news?id=c449d2c711b077dad1110e90947c3179c50be8d13e52b3b16dc479d4fec8d830",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731937075,
      "headline": "Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients",
      "id": 131456312,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302270618/image_1302270618.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it prepares for the ARTEMIS study in 2025.",
      "url": "https://finnhub.io/api/news?id=c449d2c711b077dad1110e90947c3179c50be8d13e52b3b16dc479d4fec8d830"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s Elahere wins European approval for certain ovarian cancers",
    "summary": "The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.",
    "url": "https://finnhub.io/api/news?id=4843f793ac2e9e783692896fb20264d32bdbca29bdca5f410fec8cf496c7c512",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731931622,
      "headline": "AbbVie’s Elahere wins European approval for certain ovarian cancers",
      "id": 131445736,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/shutterstock_2371012727-e1731926352685.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.",
      "url": "https://finnhub.io/api/news?id=4843f793ac2e9e783692896fb20264d32bdbca29bdca5f410fec8cf496c7c512"
    }
  },
  {
    "ts": null,
    "headline": "Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip",
    "summary": "Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira.  The drugmaker has rebounded quite nicely since.  AbbVie returned to top-line growth in the second quarter, much earlier than many anticipated.",
    "url": "https://finnhub.io/api/news?id=a302973fb7157584a7a764e527994965456f2c080a0ab808e69f4d6039d7c8fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731931200,
      "headline": "Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip",
      "id": 131456390,
      "image": "https://g.foolcdn.com/editorial/images/797774/doctor-holding-elderly-patients-hand.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira.  The drugmaker has rebounded quite nicely since.  AbbVie returned to top-line growth in the second quarter, much earlier than many anticipated.",
      "url": "https://finnhub.io/api/news?id=a302973fb7157584a7a764e527994965456f2c080a0ab808e69f4d6039d7c8fa"
    }
  },
  {
    "ts": null,
    "headline": "High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy",
    "summary": "The current market presents a complex mix of opportunities and risks. Check out my picks that include high-quality, dividend-paying stocks.",
    "url": "https://finnhub.io/api/news?id=1c693bfd27ac46a0aad99daec1003c600de7f24cfecb90ed0798ffba8fa51fbf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731915000,
      "headline": "High-Conviction Investing - 4 Of The Best Dividend Stocks Money Can Buy",
      "id": 131440355,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182795016/image_182795016.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The current market presents a complex mix of opportunities and risks. Check out my picks that include high-quality, dividend-paying stocks.",
      "url": "https://finnhub.io/api/news?id=1c693bfd27ac46a0aad99daec1003c600de7f24cfecb90ed0798ffba8fa51fbf"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer",
    "summary": "By Colin Kellaher AbbVie has won European Commission approval of Elahere to treat adult patients with a type of ovarian cancer. AbbVie on Monday said the green light covers Elahere for...",
    "url": "https://finnhub.io/api/news?id=eb3ff8a9222cd28f4d9e337d61bdee5afddb8941071b9226766912101ef4194b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731912011,
      "headline": "AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer",
      "id": 131439568,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie has won European Commission approval of Elahere to treat adult patients with a type of ovarian cancer. AbbVie on Monday said the green light covers Elahere for...",
      "url": "https://finnhub.io/api/news?id=eb3ff8a9222cd28f4d9e337d61bdee5afddb8941071b9226766912101ef4194b"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer",
    "summary": "AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. ELAHERE is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine approved i",
    "url": "https://finnhub.io/api/news?id=4910f6b057a0a0e99ca8ef297a0b9ebbfe1e998ffbd83aea620989fa01477806",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731909600,
      "headline": "AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer",
      "id": 131438590,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. ELAHERE is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine approved i",
      "url": "https://finnhub.io/api/news?id=4910f6b057a0a0e99ca8ef297a0b9ebbfe1e998ffbd83aea620989fa01477806"
    }
  }
]